{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:02:12Z","timestamp":1648548132640},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1994]]},"DOI":"10.1007\/bf00686910","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T12:13:11Z","timestamp":1101643991000},"page":"S5-S8","source":"Crossref","is-referenced-by-count":2,"title":["The effect of dose intensity on M-VAC therapy for advanced urothelial cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Naoto","family":"Miyanaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Shimazui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikinobu","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkichi","family":"Koiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.1989.7.11.1677","volume":"7","author":"PT Ang","year":"1989","unstructured":"Ang PT, Buzdar AU, Smith TL, Kau S, Hortobagyi GN (1989) Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7:1677","journal-title":"J Clin Oncol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0022-5347(17)37468-2","volume":"147","author":"Y Aso","year":"1992","unstructured":"Aso Y, Akaza H (1992) Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urological cancer. J Urol 147:1060","journal-title":"J Urol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/oxfordjournals.annonc.a057796","volume":"1","author":"H Gurney","year":"1990","unstructured":"Gurney H, Crowther D, Anderson H, Murphy D, Prendiville J, Ranson M, Mayor P, Swindell R, Buckley CH, Tindall VR (1990) Five year follow-up and dose delivery analysis of cisplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann Oncol 1:427","journal-title":"Ann Oncol"},{"key":"CR4","first-page":"3","volume":"14","author":"WM Hryniuk","year":"1987","unstructured":"Hryniuk WM, Figueredo A, Goodyear M (1987) Applications of dose intensity to problems in chemotherapy. Semin Oncol 14:3","journal-title":"Semin Oncol"},{"key":"CR5","first-page":"38","volume-title":"General rules for clinical and pathological studies on bladder cancer","author":"Japanese Urological Association and the Japanese Society of Pathology","year":"1993","unstructured":"Japanese Urological Association and the Japanese Society of Pathology (1993) General rules for clinical and pathological studies on bladder cancer, 2nd edn. Kanehara, Tokyo, p 38","edition":"2nd edn."},{"key":"CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00685108","volume":"27","author":"T Kotake","year":"1991","unstructured":"Kotake T, Miki T, Akaza H, Kubota Y, Nishio Y, Matsumura Y, Ota K, Ogawa N (1991) Effect of recombinant granulocyte colonystimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol 27:253","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"CR7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00686950","volume":"30","author":"T Kotake","year":"1992","unstructured":"Kotake T, Akaza H, Isaka S, Kagawa S, Koiso K, Machida T, Maru A, Matsumura Y, Miyagawa I, Niijima T, Obata K, Ohashi Y, Ohe H, Ohi Y, Okajima E, Sakata Y, Shimazaki J, Tashiro K, Togashi M, Ueda T, Uyama T, Yoshikawa K, the Japanese Urological Cancer Research Group for Adriamycin (1992) Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer. Cancer Chemother Pharmacol 30 [Suppl]:S85","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR8","first-page":"115","volume-title":"Development of anticancer drugs and response criteria","author":"Y Koyama","year":"1985","unstructured":"Koyama Y (1985) Response criteria for the chemotherapy of solid tumors. In: Saito T (ed) Development of anticancer drugs and response criteria. Realize Inc., Tokyo, p 115"},{"key":"CR9","first-page":"22","volume":"16","author":"RF Ozols","year":"1989","unstructured":"Ozols RF (1989) Cisplatin dose intensity. Semin oncol 16:22","journal-title":"Semin oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.1988.6.6.1031","volume":"6","author":"RF Ozols","year":"1988","unstructured":"Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC (1988) A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 6:1031","journal-title":"J Clin Oncol"},{"key":"CR11","first-page":"389","volume":"11","author":"B Piura","year":"1990","unstructured":"Piura B, Glezerman M, Cohen Y (1990) Experience in the treatment of epithelial ovarian carcinoma with cisplatinum-containing combination chemotherapy and dose intensity calculation. Eur J Gynaecol Oncol 11:389","journal-title":"Eur J Gynaecol Oncol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/1097-0142(19840301)53:5<1029::AID-CNCR2820530503>3.0.CO;2-Z","volume":"53","author":"MK Samson","year":"1984","unstructured":"Samson MK, Rivkin WE, Jones SE, Costanzi JJ, Lobuglio AF, Stephens RL, Gehan EA, Cummings GD (1984) Dose response and dose-survival advantage for high- versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 53:1029","journal-title":"Cancer"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ssu.2980080511","volume":"8","author":"HI Scher","year":"1992","unstructured":"Scher HI, Norton L (1992) Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol 8:316","journal-title":"Semin Surg Oncol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/JCO.1993.11.3.400","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher HI, Geller NL, Curley T, Tao Y (1993) Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11:400","journal-title":"J Clin Oncol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1200\/JCO.1993.11.3.408","volume":"11","author":"AD Seidman","year":"1993","unstructured":"Seidman AD, Scher HI, Gabrilove JI, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quilivan S, Tao Y, Fair WR, Begg C, Bosl GJ (1993) Dose intensification of methotrexate, vinblastine, doxorubicin, and cisplatin with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408","journal-title":"J Clin Oncol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","volume":"64","author":"CN Sternberg","year":"1989","unstructured":"Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin S, Penenberg D, Fair WR, Whitmore WF Jr (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cell carcinoma of the urothelium. Cancer 64:2448","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686910\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T06:11:08Z","timestamp":1554444668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":16,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1994]]}},"alternative-id":["BF00686910"],"URL":"https:\/\/doi.org\/10.1007\/bf00686910","relation":{},"ISSN":["0943-9404","1432-0843"],"issn-type":[{"value":"0943-9404","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994]]}}}